Aethlon Medical Treats First Patient in Australian Hemopurifier® Cancer Trial

Stock Information for TCR2 Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About TCR2 Therapeutics Inc.

Aethlon Medical Announces Publication of Preclinical Data Showing Ability of the Hemopurifier® to Remove Platelet-Derived Extracellular Vesicles from Plasma
Presenting on the Emerging Growth Conference 80, Day 1 on March 26 - Register Now
Aethlon Medical Publishes Preclinical Data on the Hemopurifier® in Transplant Immunology Journal
Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now
Aethlon Medical to Present at the Emerging Growth Conference on February 19, 2025
Aethlon Medical Announces Financial Results for the Fiscal Third Quarter Ended December 31, 2024 and Provides Corporate Update
Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2025
Aethlon Medical Provides Update on the Ability of Its Hemopurifier® to Capture H5N1 Bird Flu

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.